<![CDATA[Background: Chemotherapy-induced peripheral neuropathy (CIPN) is chemotherapy’s side effect that can last for years even after treatment stopped. The prevalence after chemotherapy is 68% in the first month. Chemotherapy’s main mechanism is the disruption of the depolymerization cycle of microtubules in the myelin sheath, which interferes with nerve transmission and causes tingling, numbness, and severe pain. Current management of CIPN are antidepressant medications, such as duloxetine, and gabapentinoids (pregabalin and gabapentin). Objective: This systematic review aims to provide comparison of the efficacy and safety between two drugs in reducing neuropathy on CIPN patients, due to lack of previous systematic review on this topic. Methods: A literature review search was conducted in the PubMed database, Sage Journal, and other sources until the date 10th September 2025. Results: Using VAS score, duloxetine showed less capability to lower pain which is around 30.5%, while gabapentinoid by VAS score showed around 73.4%. But when it comes to adverse effect, duloxetine suggested more less severity, such as nausea, dizziness, fatigue, headache, and insomnia; whereas gabapentinoid can cause somnolence, dizziness, ataxia, diplopia, blurred vision, sedation, drowsiness, pedal edema, swelling of the face and eyelids, while the rest developed excessive sedation. Conclusions: Duloxetine is effective and consistent in reducing CIPN compared to gabapentinoids; with gabapentin being superior to pregabalin. This review’s limitation lies in the few studies discussing the efficacy of both drugs on CIPN.]]>
